These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 22481406)

  • 21. The potential benefits of BIM in the further pursuit of biomarker discovery in cancer therapeutics.
    Yoshida T; Haura EB
    Cancer Discov; 2011 Sep; 1(4):289-90. PubMed ID: 22586609
    [TBL] [Abstract][Full Text] [Related]  

  • 22. c-Abl kinase inhibitors overcome CD40-mediated drug resistance in CLL: implications for therapeutic targeting of chemoresistant niches.
    Hallaert DY; Jaspers A; van Noesel CJ; van Oers MH; Kater AP; Eldering E
    Blood; 2008 Dec; 112(13):5141-9. PubMed ID: 18796631
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A multicenter phase II study of sorafenib monotherapy in clinically selected patients with advanced lung adenocarcinoma after failure of EGFR-TKI therapy (Chinese Thoracic Oncology Group, CTONG 0805).
    Zhou Q; Zhou CC; Chen GY; Cheng Y; Huang C; Zhang L; Xu CR; Li AW; Yan HH; Su J; Zhang XC; Yang JJ; Wu YL
    Lung Cancer; 2014 Mar; 83(3):369-73. PubMed ID: 24440279
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gefitinib-resistance is related to BIM expression in non-small cell lung cancer cell lines.
    Li H; Zhou S; Li X; Wang D; Wang Y; Zhou C; Schmid-Bindert G
    Cancer Biother Radiopharm; 2013 Mar; 28(2):115-23. PubMed ID: 23270470
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synergistic activity and heterogeneous acquired resistance of combined MDM2 and MEK inhibition in KRAS mutant cancers.
    Hata AN; Rowley S; Archibald HL; Gomez-Caraballo M; Siddiqui FM; Ji F; Jung J; Light M; Lee JS; Debussche L; Sidhu S; Sadreyev RI; Watters J; Engelman JA
    Oncogene; 2017 Nov; 36(47):6581-6591. PubMed ID: 28783173
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Paxillin confers resistance to tyrosine kinase inhibitors in EGFR-mutant lung cancers via modulating BIM and Mcl-1 protein stability.
    Wu DW; Chen CY; Chu CL; Lee H
    Oncogene; 2016 Feb; 35(5):621-30. PubMed ID: 25915848
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Different effects of the BIM deletion polymorphism on treatment of solid tumors by the tyrosine kinase inhibitors (TKI) pazopanib, sunitinib, and lapatinib.
    Spraggs CF; Parham LR; Song K; Briley LP; Johnson T; Russo M; Tada H; du Bois A; Xu CF
    Ann Oncol; 2015 Jul; 26(7):1515-7. PubMed ID: 25922065
    [No Abstract]   [Full Text] [Related]  

  • 28. Clinical significance of epidermal growth factor receptor tyrosine kinase inhibitors: sensitivity and resistance.
    Takeuchi S; Yano S
    Respir Investig; 2014 Nov; 52(6):348-56. PubMed ID: 25453378
    [TBL] [Abstract][Full Text] [Related]  

  • 29. H2AX phosphorylation regulated by p38 is involved in Bim expression and apoptosis in chronic myelogenous leukemia cells induced by imatinib.
    Dong Y; Xiong M; Duan L; Liu Z; Niu T; Luo Y; Wu X; Xu C; Lu C
    Apoptosis; 2014 Aug; 19(8):1281-92. PubMed ID: 24830786
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MiR-494 is regulated by ERK1/2 and modulates TRAIL-induced apoptosis in non-small-cell lung cancer through BIM down-regulation.
    Romano G; Acunzo M; Garofalo M; Di Leva G; Cascione L; Zanca C; Bolon B; Condorelli G; Croce CM
    Proc Natl Acad Sci U S A; 2012 Oct; 109(41):16570-5. PubMed ID: 23012423
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The roles of epigenetic modifications of proapoptotic BID and BIM genes in imatinib-resistant chronic myeloid leukemia cells.
    Bozkurt S; Özkan T; Özmen F; Baran Y; Sunguroğlu A; Kansu E
    Hematology; 2013 Jul; 18(4):217-23. PubMed ID: 23394612
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms.
    Paraiso KH; Haarberg HE; Wood E; Rebecca VW; Chen YA; Xiang Y; Ribas A; Lo RS; Weber JS; Sondak VK; John JK; Sarnaik AA; Koomen JM; Smalley KS
    Clin Cancer Res; 2012 May; 18(9):2502-14. PubMed ID: 22351686
    [TBL] [Abstract][Full Text] [Related]  

  • 33. EGFR inhibition evokes innate drug resistance in lung cancer cells by preventing Akt activity and thus inactivating Ets-1 function.
    Phuchareon J; McCormick F; Eisele DW; Tetsu O
    Proc Natl Acad Sci U S A; 2015 Jul; 112(29):E3855-63. PubMed ID: 26150526
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Heritable resistance to tyrosine kinase inhibitors.
    Ong ST
    Clin Adv Hematol Oncol; 2014 Jul; 12(7):454-7. PubMed ID: 25322326
    [No Abstract]   [Full Text] [Related]  

  • 35. BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors.
    Faber AC; Corcoran RB; Ebi H; Sequist LV; Waltman BA; Chung E; Incio J; Digumarthy SR; Pollack SF; Song Y; Muzikansky A; Lifshits E; Roberge S; Coffman EJ; Benes CH; Gómez HL; Baselga J; Arteaga CL; Rivera MN; Dias-Santagata D; Jain RK; Engelman JA
    Cancer Discov; 2011 Sep; 1(4):352-65. PubMed ID: 22145099
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Proapoptotic BH3-only BCL-2 family protein BIM connects death signaling from epidermal growth factor receptor inhibition to the mitochondrion.
    Deng J; Shimamura T; Perera S; Carlson NE; Cai D; Shapiro GI; Wong KK; Letai A
    Cancer Res; 2007 Dec; 67(24):11867-75. PubMed ID: 18089817
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-x(L).
    Perkins C; Kim CN; Fang G; Bhalla KN
    Blood; 2000 Feb; 95(3):1014-22. PubMed ID: 10648417
    [TBL] [Abstract][Full Text] [Related]  

  • 38. GILZ inhibits the mTORC2/AKT pathway in BCR-ABL(+) cells.
    Joha S; Nugues AL; Hétuin D; Berthon C; Dezitter X; Dauphin V; Mahon FX; Roche-Lestienne C; Preudhomme C; Quesnel B; Idziorek T
    Oncogene; 2012 Mar; 31(11):1419-30. PubMed ID: 21804606
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cellular Mechanisms Underlying Complete Hematological Response of Chronic Myeloid Leukemia to BRAF and MEK1/2 Inhibition in a Patient with Concomitant Metastatic Melanoma.
    Andrews MC; Turner N; Boyd J; Roberts AW; Grigg AP; Behren A; Cebon J
    Clin Cancer Res; 2015 Dec; 21(23):5222-34. PubMed ID: 26202951
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235.
    Hall CP; Reynolds CP; Kang MH
    Clin Cancer Res; 2016 Feb; 22(3):621-32. PubMed ID: 26080839
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.